INOMAX selectively dilates the pulmonary vasculature
Inhalation of INOMAX offers selective activity
- When inhaled, nitric oxide selectively dilates the pulmonary vasculature, and because of efficient scavenging by hemoglobin, has minimal effect on the systemic vasculature4
- Targeted delivery to the pulmonary bed4
Inhalation of INOMAX offers rapid onset
- INOMAX causes vasodilation in the pulmonary vasculature by increasing cGMP levels through the activation of guanylate cyclase4
- Clinical responses seen in as little as 30 minutes11
Inhalation of INOMAX offers rapid inactivation
- Short half-life minimizes systemic effects4,12
- Rapid metabolism in the blood converts nitric oxide to metabolites that are predominantly cleared by the kidneys4
Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Therefore, methemoglobin levels should be monitored during INOMAX administration.
Please see Full Prescribing Information.